Sakar Healthcare LtdQ1 FY27
Sakar Healthcare Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹889P/E: 56.3Market Cap: ₹2.0K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 1
Margin
Category 1
Fundraise
No
Order
Yes
Capex
No
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 1- →Oncology revenue expected to double from INR100 crores in FY26 to INR200 crores in FY27, and triple to around INR280-300 crores in FY28.
- →Total oncology revenue potential estimated between INR800 crores to INR1,000 crores within 3-4 years.
- →Export business contribution expected to rise to about 30% of oncology sales by FY27, driven by marketing authorizations and site variations.
- →Domestic CMO business for oncology targeted to double from approximately INR35 crores in FY26 to about INR70 crores in FY27.
- →Non-oncology (CDMO and API) business expected to grow steadily at 7-8% CAGR in line with generic market trends.
- →Increasing marketing authorizations (current 16, targeting over 100 by FY28) to drive export growth and revenue doubling each year.
- →Backward integration with API and CEP approvals to improve margins and support scalable growth.
Margin guidance
Category 1- →Oncology business expected to nearly double revenue from INR100 crores to INR200 crores in FY27 and triple to INR280-300 crores in FY28.
- →EBITDA margins projected to improve from ~27% to around 30% in oncology by year-end FY27.
- →API integration anticipated to further increase EBITDA margins to approximately 35% or higher in oncology segments within 2-3 quarters.
- →Overall revenue growth driven by doubling oncology sales and steady 7-8% CAGR growth in non-oncology business.
- →Profit after tax showed strong growth of 120% YoY in Q1 FY27, indicating robust profitability trajectory.
- →Increase in marketing authorizations and dossiers (targeting 100+ approvals next year) expected to support continued strong top-line and profitability growth.
3 more insights locked — sign up free to unlock
Fundraise plans
No- →Currently, Sakar Healthcare Limited does not have any plans for new fundraising through debt or equity.
- →The company is self-sufficient in funding its business developments and product pipelines.
- →Existing projects and product developments were planned years ahead and are being executed without reliance on external funding or government grants.
- →No government grants or additional funding are being pursued at this time for R&D or expansion.
Order book
Yes- →Sakar Healthcare currently has over 250 dossiers registered or in pipeline for export markets, indicating a strong orderbook for oncology products.
- →178 dossiers have already been submitted to regulatory agencies worldwide, with 16 marketing authorizations (MAs) approved so far.
- →Another 50-plus dossiers are expected to be submitted within the next 1-2 quarters, with an addition of around 25-30 dossiers every quarter going forward.
- →The company has completed more than 50-60 export agreements/contracts overseas and 15 contracts in the domestic market.
- →They are targeting to double the dossier approvals this financial year to over 100 and aim for 100+ approvals next financial year, which will significantly boost the orderbook.
- →The current quarterly run-rate is INR70-75 crores, with expectations to reach INR90 crores in upcoming quarters due to increased export contributions.
Capex plans
No- →No further capex or capital investment is planned for the next few years as the current facility supports ongoing and upcoming product development.
- →The existing setup is sufficient to commercialize 6-7 additional molecules coming off-patent in the next couple of years without requiring expansion.
- →Focus remains on expanding dossier submissions, regulatory approvals, and commercialization within the current infrastructure.
- →Investment is primarily directed towards backward integration of APIs with CEP certifications to improve margins and operational robustness.
- →R&D and product development are internally funded, with no current plans for external government or agency grants.
How does Sakar Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Sakar Healthcare Ltd
Rev 1Mar 1
See full Pharmaceuticals & Biotechnology sector rankings
How does Sakar Healthcare Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sakar Healthcare Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.